Oxford Nanopore Technologies (ONT) 21st Annual Goldman Sachs European Medtech and Healthcare Conference summary

Business overview and technology differentiation

• Offers long-read DNA and RNA sequencing using electronic, non-optical platforms, enabling real-time, high-definition data at lower cost and with greater flexibility than traditional short-read, optical-based systems.

• Long-read sequencing addresses previously inaccessible genomic regions, revealing structural and copy number variations linked to complex diseases and enabling comprehensive methylation analysis.

• Devices range from portable, point-of-origin sequencers to large-scale platforms, supporting both decentralized and population-scale genomics.

• Achieved accuracy parity with short-read sequencing after significant R&D, now focusing on unique value propositions like speed, near-patient testing, and multi-omics capabilities.

• Commercial model includes affordable device access and OpEx-based bundles, broadening market reach beyond large, capital-intensive labs.

Financial performance and growth outlook

• Reported 12.4% underlying revenue growth to £84 million in H1, maintaining full-year guidance of 20%-30% growth despite a challenging market.

• Gross margin improved to 58.8%, driven by manufacturing efficiencies, especially in consumables, and increased utilization of larger platforms.

• Expanded commercial infrastructure, with field sales headcount up 80% year-over-year, and improving sales force efficiency expected to drive future growth.

• Confident in achieving full-year growth targets, supported by new product launches and strong visibility into H2 opportunities.

• China remains a growth market despite regulatory hurdles, with 7.5% underlying growth in H1 and increasing consumable utilization.

Market trends and strategic positioning

• Long-read sequencing is gaining traction in population-scale genomics, rare disease screening, and biopharma, with recent wins in Asia-Pacific and applied markets.

• Multi-omics, especially methylation analysis, is a key differentiator, with built-in capabilities for simultaneous genome and epigenome analysis.

• Regulatory-compliant Q-Line products target clinical and biopharma markets, with partnerships (e.g., bioMérieux) facilitating entry into regulated segments.

• Applied markets like plasmid sequencing represent significant white space, with service providers rapidly adopting the technology for cost and accuracy advantages.

• Scalability and cost reduction roadmap positions the company to offer premium, fully annotated genomes at competitive prices for large-scale programs.